BioSpace News Archive

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported fourth quarter and full year 2021 financial results and recent operational progress.

Histogen Inc. reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its clinical pipeline and other corporate developments.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided corporate updates.

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2021 and provided an overview of recent business highlights.

Homology Medicines, Inc., a genetic medicines company, announced the successful closing of the deal with Oxford Biomedica plc to establish an Adeno-Associated Virus Manufacturing and Innovation Business.

Anika Therapeutics, Inc. announced that management will participate at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March 22, 2022 at 9:30 a.m. CT.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases, reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results.